Expanding research applications with scaled real-world response
In the ever-evolving oncology landscape, the significance of understanding treatment response outside of a clinical trial setting is growing. Today’s researchers are harnessing real-world data (RWD) to characterize a target drug’s clinical effectiveness within real-world settings and to conduct impactful comparative effective analyses across populations or therapies. As the horizon for use cases continues to expand, an apparent need emerges: to deliver this invaluable information to researchers on a larger scale.
Flatiron Health is now able to deliver a scaled version of real-world response, which characterizes changes in disease burden based on a clinician’s interpretation of radiology assessments. This is one of our most critical and frequently-requested variables because of its value in quantifying patient outcomes. Now, real-world response can be offered from an unprecedented number of patients.
Flatiron’s data at scale offers the quality you need, faster than ever before. Leveraging cutting-edge machine learning (ML) techniques, Flatiron has elevated our capability to provide response information from unstructured data sources across various solid tumors. Our extraction approach has been trained and validated on high-quality data abstracted by humans and is based on rigorous curation processes established by clinicians.
Uncover more insights, faster
Expanding patient cohort sizes from hundreds to tens of thousands can uncover numerous insights about pivotal factors that influence treatment response. Flatiron can quickly deliver high quality real-world evidence (RWE) across the oncology drug life cycle, including discovery, clinical trial planning, and market access. With this newly available real-world response offering, researchers can now decode answers across solid tumors in ways that were previously infeasible.
Learn more about our oncology real-world evidence solutions
Interested in seeing how Flatiron’s RWE solutions transform the possibilities of oncology research, development, and commercialization?
